News >

New Agents on Horizon for HER2-Positive Breast Cancer

Danielle Bucco
Published: Thursday, Apr 12, 2018

Frances Valdes-Albini, MD

Frances Valdes-Albini, MD
There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD, assistant professor of clinical medicine at the University of Miami Miller School of Medicine.

State of the Science Summit™ on Breast Cancer, Albini discussed the novel treatment approaches being developed in the HER2-positive breast cancer paradigm.

Margetuximab

In the phase III randomized SOPHIA trial, margetuximab plus chemotherapy is being compared with trastuzumab (Herceptin) plus chemotherapy in the treatment of patients with HER2-positive metastatic breast cancer (NCT02492711). The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression-free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x